THERAPEUTIC RESULTS OF MANTLE CELLS LYMPHOMAS AT THE SIDI-BEL-ABBES HEMATOLOGY DEPARTMENT

Authors: N. Siali, k. Tayebi A. Hadjeb, M. Benlazar
Hematology Department, Sidibelabbes University Hospital

Introduction

Mantle cell lymphoma (MCL) is rare and aggressive. Treatment is based on a combination of cytarabine and rituximab, with autologous transplantation in young patients. MCL is marked by relapses. However, targeted therapies are likely to modify the


treatment and prognosis of the disease ■


Aim

The aim of this study is to define the clinical and therapeutic epidemiological characteristics of patients with MCL.

Methods

This is a retrospective, single-center study of patients (pts) with MCL between 2010 and 2022, and a study of clinical and therapeutic epidemiological characteristics with calculation of overall survival according to Kaplan and Meier.





Sex ratio=3

Results

In total, 20 (pts) LCM were collected, including 15 men and 5 women, Sex Ratio (M/F) = 3, median age = 70 years, extremes (23-84) The diagnosis made on a lymph node biopsy: 13/20 pts (60%), flow cytometry (FCM): 8/20 pts (30%), and on both: 2/20 pts (10%). Stage I: 2/20 pts (10%), stage III: 8/20 pts (40%), stage IV: 10/20 pts (50%). According to the MIPI prognostic score; low: 7/20 pts (35%), intermediate: 12/20 pts (60%), and high: 1/20 pts (5%). Pts received chemotherapy according to age and comorbidities: CVP: 6/20 pts (30%), RCHOP: 9/20 pts (45%), RBENDA: 4/20 pts (20%), RBAC: 1/20 pts (5%) Complete remission (CR): 9/20 pts (45%), partial remission (PR): 6/20 pts (30%) and failure: 5/20 pts (25%), Death: 8/20 pts (40%) including 2 pts (25%) from Covid and 6 pts (75%) from progression or failure, late relapses: 4 pts (20%). Overall survival at 5 years = 60%, median survival = 70 months

Summary

Despite the undeniable progress made in recent years, MCL remains a serious disease, particularly for relapsing or refractory patients, in whom the outcome is often poor. Treatment of relapsed or refractory patients is based on BTK inhibitors.

References

1-Les lymphomes non Hodgkiniens, John Libbey Eurotext
2-Hematologie John Sebahnoun
3-Revue Algérienne d'hématologie N° 13 et 14 décembre 2017